期刊文献+

缬沙坦和福辛普利对急性心肌梗死后左心室重塑的疗效比较 被引量:3

下载PDF
导出
摘要 目的观察缬沙坦和福辛普利对急性心肌梗死(AMI)患者,左心室重塑(LVRM)的治疗效应并进行比较。方法 AMI患者75例,随机分为3组。缬沙坦组25例,福辛普利组26例,对照组24例。对照组给予长效硝酸酯类、肠溶阿司匹林、肝素?β-受体阻滞剂、他汀等常规治疗;缬沙坦组在常规治疗基础上加用缬沙坦80mg口服,1次/d,福辛普利组在常规治疗基础上加用福辛普利20mg口服,1次/d。分别在入院第1天、14天、6个月时采用超声心动图,测定左心室舒张末期内径(LVDd)、左心室收缩末期内径(LVDs)、左心室射血分数(LVEF)并进行比较。结果对照组14天及6个月时LVDd、LVDs较基础值增加,有显著性差异(P<0.05);缬沙坦组与福辛普利组LVDd、LVDs变化无显著性差异(P>0.05);福辛普利组咳嗽发生率11.5%?缬沙坦组无1例发生副反应。结论缬沙坦与福辛普利具有相似的抗左心室重塑的治疗效果缬沙坦组耐受性更好。
作者 赵玉娟
出处 《中国实用医药》 2010年第15期197-198,共2页 China Practical Medicine
  • 相关文献

参考文献4

  • 1White H D,Norris R M,Brown M A,et al.Left ventricular end-systolic volume as the major determinant of survival after recovery from myocaridial infarction.Circulation,1987,76(1):44-51.
  • 2Goodfriend T L,Elliotc M E,Cao K J,et al.Angiotensin receptors and their antagonist.N Eng J Med,1996,334(6):1649-1661.
  • 3Andreas J,Rainer S,Hilmar D,et al.Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation,bradykinin and prostaglandins in pigs.J Am Coll Cardiol,1998,32(7):1787-796.
  • 4Schieffer B,Wirger A,Meybrum M,et al.Comparative effects of chronic angiotensin-coverting enzyme inhibition I type l receptor blockade on cardiac remodeling after myocardial infarction in the rat.Circulation,1994,89(10):2273-2282.

同被引文献30

  • 1李峥,郑文丽,吴洪.冠心宁注射液对急性心肌梗死后左室重构的影响[J].中国中西医结合急救杂志,2007,14(4):227-230. 被引量:6
  • 2Simon T, Mary- Krause M, Funck- Brentano C, et al. Bisoprohol dose-response relationship in patients, with congestive heart failure, a sub group analysis in the cardiac insufficiency bisoprolol study (CIBISI/4)[J]. Eur Heart J, 2003, 24(6) : 552-559.
  • 3Solomon SD, Hee Shin S, Shah A, et al. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction[J]. Enr Heart J, 2011, 32(10): 1227-1234.
  • 4Cesari M, Pedone C, Incalzi RA, et al. ACE-inhibition and physical function: results from the Trial of Angioten-sin-Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors(TRAIN)study [J]. J Am Med Dir Assoc, 2010, 11(1): 26-32.
  • 5K/DOQI clinical practice guidelines for chronic kidney disease: evaluation classification and stratification. Am J Kidney Dis, 2002,39 ( 2 ) :241-246.
  • 6Anand IS,Deswal A,Kereiakes DJ,et al. Comparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failure[J]. Vasc Health Risk Manag,2010,6:449-55.
  • 7Flores LJ,Figueroa D,Sanches IC,et al. Effects of exercise training on autonomic dysfunction management in an experimental model of menopause and myocardial infraction[J]. Menopause,2010,17(4):712-7.
  • 8Masson S,Solomon S,Angelici L,et al. Elevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacologic therapy: data from the Valsartan Heart Failure Trial (Val-HeFT)[J]. J Card Fail,2010,16(12):964-70.
  • 9无.慢性心力衰竭诊断治疗指南[J].中华心血管病杂志,2007,35(12):1076-1095. 被引量:3693
  • 10庞海燕,王林,马金萍,陈康寅,陈树涛,李广平,黄体钢.ACEI在慢性心力衰竭药物治疗中应用现状调查分析[J].天津医药,2008,36(1):29-31. 被引量:3

引证文献3

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部